ArticleJournal of internal medicine2025
Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care.
Article in Journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MASLD and sarcopenia research (2012-2025): a multi-database bibliometric analysis.Frontiers in nutrition · 2026Pooled it
- Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications.BMJ open gastroenterology · 2026Review
- Integrating MASLD detection into diabetes care in primary care settings in Mexico: A cascade analysis.Clinical medicine (London, England) · 2026Article
- Prevalence and associated factors of liver fibrosis and steatosis in Gansu, China: a community-based cross-sectional study.BMC public health · 2026Article
- The central role of hyperandrogenism in driving metabolic dysfunction in polycystic ovary syndrome: from pathophysiological mechanisms to targeted therapies.Journal of ovarian research · 2026Review
- An Explainable AI Tool (FibroX) for Detecting Advanced Liver Fibrosis in Adults With Type 2 Diabetes: Protocol for a Pilot Crossover Trial.JMIR research protocols · 2026Article
- Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort.Journal of internal medicine · 2026Article
- Multi-omics integration reveals ANXA6-high γδ T cell-endothelial communication as a potential link between periodontitis and MASLD.NPJ systems biology and applications · 2026Article
- Associations of relative fat mass with metabolic dysfunction-associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017-2023.BMC gastroenterology · 2026Article
- Association Between Sarcopenic Obesity-Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Intrinsic capacity, genetic susceptibility, and the risks of metabolic dysfunction-associated steatotic liver disease and cirrhosis.International journal of surgery (London, England) · 2026Article
- Microvascular complications of type 2 diabetes with or without MASLD: the EPSOMIP study, a primary care cohort study.BMC primary care · 2025Observational
- Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care.Journal of internal medicine · 2025Article
- Ultra-Processed Foods and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): What Is the Evidence So Far?Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
BACKGROUND AND
aimsThe prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased during the epidemic of obesity. Type 2 diabetes mellitus (T2DM) is associated with progressive MASLD. Therefore, many guidelines recommend screening for MASLD in patients with T2DM. Most studies in patients with MASLD have been conducted in specialist care. We investigated the prevalence and severity of MASLD in patients with T2DM from primary care.
methodsPatients with T2DM were prospectively included from primary care facilities to undergo transient elastography with controlled attenuation parameter and whole-body magnetic resonance imaging (MRI) to assess liver fat, cardiac function, muscle composition, and distribution of body fat.
resultsAmong 308 participants, 59% had MASLD, 7% had suspected advanced fibrosis (transient elastography ≥ 10 kPa), and 1.9% had cirrhosis. The mean age was 63.9 ± 8.1 years; 37% were female, with no differences between the MASLD and the non-MASLD groups. Participants with MASLD had greater body mass index (31.1 ± 4.4 vs. 27.4 ± 4.1 kg/m
conclusionsIn this cohort of primary care patients with T2DM, 59% had MASLD, and 7% had suspected advanced fibrosis. Obesity was a strong predictor of fibrotic MASLD. MASLD was associated with alterations to the left ventricle and increased deposition of ectopic fat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.